Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

CRN Clinical Research Network LLC

Neither a doctor nor a teaching hospital

Research payments

$17,080,193

4,955 payments

Through program year 2025, CRN Clinical Research Network LLC is reported as receiving $17,080,193 in research payments, across 4,955 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,574,818 868
2024 Research $2,627,612 1,161
2023 Research $3,968,434 1,817
2022 Research $953,321 413
2021 Research $1,026,815 370
2020 Research $1,555,359 129
2019 Research $3,373,835 197

Breakdown

Who paid Research payments · program years 2019–2025
  1. Cipla USA Inc. $5,936,195 1,394 payments
  2. Teva Pharmaceuticals USA, Inc. $5,017,047 1,285 payments
  3. Chiesi USA, Inc. $4,040,140 1,597 payments
  4. GlaxoSmithKline, LLC. $1,250,183 227 payments
  5. Sanofi US Services Inc. $400,509 50 payments
  6. Regeneron Pharmaceuticals, Inc. $365,469 391 payments
  7. Pfizer Inc. $67,577 10 payments
  8. Genzyme Corporation $3,075 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. U-Fs-Mu-As3120 $3,551,968 211 payments
  2. A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. $2,943,799 1,125 payments
  3. A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma $1,376,060 507 payments
  4. A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, 4-Week Clinical Endpoint Bioequivalence Study Comparing Fluticasone Propionate/Salmeterol 100/50 Micro GM Inhalation Powder With Advair Diskus 100/50 Micro GM in Asthma Patients $1,369,989 122 payments
  5. A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma $1,203,086 107 payments
  6. A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma $1,155,293 263 payments
  7. A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. $1,056,356 444 payments
  8. A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Para $851,746 119 payments
  9. A Randomized, Open Label, Active-Controlled, Parallel-Group, Multiple-Dose, Multiple-Site, Patient Use Study to Obtain Partially Used Test Fluticasone Propionate Inhalation Aerosol, 110 mcg (Teva) Devices and Reference FLOVENT HFA (fluticasone propionate inhalation aerosol), 110 mcg (GlaxoSmithKline) Devices, After Repeated Use in Patients with Asthma $726,110 42 payments
  10. A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma $544,613 239 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record